Company Description
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01...
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.
Valuation
Price to Book Ratio
1.63
Enterprise Value to EBITDA
-0.62
Total Debt to Enterprise Value
0.00
Efficiency
Income Per Employee
-1,096,808.00
Liquidity
Current Ratio
4.25
Quick Ratio
4.25
Cash Ratio
3.31
Profitability
Return on Assets
-134.16
Return on Equity
-156.34
Return on Total Capital
-162.80
Return on Invested Capital
-156.20
Capital Structure
Total Debt to Total Equity
0.20
Total Debt to Total Capital
0.20
Total Debt to Total Assets
0.16
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Pardeep Nijhawan | 51 | 2015 | Chief Executive Officer, Secretary & Director |
Dr. Michael Brooks | 41 | 2015 | Vice President- Corporate Development & Strategy |
Mr. Stephen L. Lemieux | 46 | 2023 | Chief Financial Officer |
Dr. Blair Gordon | - | 2016 | Vice President-Research & Development |
Mr. Rajan Puri | - | 2021 | Senior Vice President-Manufacturing |
Insider Actions
MarketWatch News on EDSA
-
Stellar Biotechnologies stock price target cut to $7 from $17 at Maxim Group
- Tomi Kilgore
-
Stellar Biotechnologies Gets a Positive Sign
- Barron's Online
Other News on EDSA
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)